Fiscal year 2025 revenue was approximately $29.2 million, with XpresSpa contributing $18.6 million, XpresCheck $8.3 million, and Naples Wax Center $2.3 million. Total operating expenses decreased by approximately 10% to $23.2 million compared to $25.6 million in the prior year. Cost of sales decreased by approximately 13% to $21.7 million from $25.0 million in 2024. General and administrative expenses saw a year-over-year decrease of approximately 20%. Operating loss improved to approximately $15.7 million from $16.7 million in the comparable prior year period. Net loss attributable to XWELL slightly increased to approximately $17.0 million from $16.9 million in the prior year. As of December 31, 2025, the company had approximately $2.6 million in cash and cash equivalents (excluding restricted cash) and no long-term debt. Subsequent to year-end, XWELL completed a private placement in February 2026, raising approximately $31.3 million in gross proceeds. Strategic expansions include new wellness retail locations in New York City's Penn Station (December 2025) and two Florida locations (Q3 2025). The company secured a three-year extension for its Traveler-based Genomic Surveillance Program (TGS) with the CDC and Ginkgo Bioworks in March 2025. A strategic partnership with PieQ was formed in February 2026 to develop a novel U.S. biosecurity forecasting platform. Dr. Cindy Friedman, former CDC senior advisor, was appointed as a senior advisor for global biosecurity initiatives in February 2026.